CAMBRIDGE, Mass., November 27, 2024--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company ...

Leerink Partners analyst Mani Foroohar has maintained their neutral stance on ALNY stock, giving a Hold rating on November 25.Don't Miss our ...

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) – Investment analysts at Zacks Research increased their FY2024 ...

In a report released today, Liisa Bayko from Evercore ISI maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...

ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...

The Conference Forum today announced the launch of the 12th annual Patients as Partners® in Clinical Research meeting, taking place March 17-19, 2025 at the Sheraton Boston, in Boston, MA. Patients as ...

Bio-Techne Corporation today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m ...

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding ...

BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...

Deal Could End Israel-Hezbollah Conflict That Has Lasted Over a Year Lebanon’s caretaker cabinet is expected to meet to formally approve the deal, in which it would play an essential role. Maps ...